Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial

Abstract Background Hypofractionated palliative radiotherapy for metastatic lung cancer patients is frequently used in order to ease pain, to increase bone stability, to treat local mass effects, or to prolong progression-free survival at critical sites. Recently introduced, immunotherapy for patien...

Full description

Bibliographic Details
Main Authors: Farastuk Bozorgmehr, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Jonas Kuon, Martin Maenz, Peter E. Huber, Laila König, Meinhard Kieser, Juergen Debus, Michael Thomas, Stefan Rieken
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
Immunotherapy
Radioimmunotherapy
Abscopal effect
PD-1
Nivolumab
Online Access:http://link.springer.com/article/10.1186/s12885-019-6205-0

Internet

http://link.springer.com/article/10.1186/s12885-019-6205-0

Similar Items